Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans he has to maintain the regulatory system for pharmaceutical medicines at the end of the transition period.

At the end of the transition period, the Medicines and Healthcare products Regulatory Agency (MHRA) will be the United Kingdom’s medicines regulator while acknowledging the special provisions that will apply in Northern Ireland for as long as the Northern Ireland Protocol is in force.

On 27 October 2020 the MHRA published guidance on the licensing regulatory system for pharmaceutical medicines that will apply after the transition period. A statutory instrument, setting out the regulatory environment for medicines from 1 January 2020, is currently before Parliament.